Amylin Pharmaceuticals, Inc. (AMLN) rated Mkt Underperform with price target $8 by Rodman & Renshaw
Rodman & Renshaw rated Mkt Underperform Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN) on 01/05/2012, when the stock price was $10.85.
Since then, Amylin Pharmaceuticals, Inc. has gained 185.16% as of 08/06/2012's recent price of $30.94. If you would have followed this Rodman & Renshaw's recommendation on AMLN, you would have lost 64.93% of your investment in 214 days.
Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN injection and BYETTA injection. Amylin's research and development activities leverage the company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is located in San Diego, California with over one thousand five hundred employees nationwide.
Rodman & Renshaw
is a full-service investment bank dedicated to providing investment banking services to companies that have significant recurring capital needs due to their growth and development strategies. We also provide research and sales and trading services to institutional investor clients that focus on such companies. Since 2003, Rodman has been a leading investment banking firm to the biotechnology sector, a capital intensive market segment, as well as a leader in the PIPE (private investment in public equity) and RD (registered direct placements) transaction markets.